City of Hope researchers to share new immunotherapy and precision medicine insights across cancer types at ASCO 2026
Reports and Proceedings
Updates every hour. Last Updated: 17-May-2026 19:15 ET (17-May-2026 23:15 GMT/UTC)
Researchers from City of Hope®, one of the largest and most advanced cancer research and treatment organizations in the United States, will present 49 abstracts at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, including new findings on immunotherapy, precision medicine and emerging treatment strategies across blood cancers and solid tumors.
Scientists from the Max Planck Institute for Marine Microbiology discover that a group of beneficial gut bacteria and their marine relatives use the same feeding strategies. This sheds new light on the potential of these bacteria for gut health research, as well as their role in marine carbon cycling.
Researchers at Washington University School of Medicine in St. Louis have identified a previously unknown biological process that helps explain why only a subset of patients with alpha1-antitrypsin deficiency develop liver disease.
A new review in Current Cardiology Reviews maps how heart failure management is shifting toward precision medicine—pairing proven therapies (notably SGLT2 inhibitors across the ejection fraction spectrum) with biomarker panels, advanced imaging, genetics, and AI-enabled monitoring. The article highlights major breakthroughs (including disease-specific treatments such as transthyretin amyloidosis therapies), ongoing gaps in access and trial representation, and practical priorities to bring personalized, equitable heart failure care into routine practice.